Table 2. Results from CVD and cancer systematic reviews: all comparisons aspirin vs. control.
| Published studies and Reported pooled estimates | Re-analysis of reported data | |||||
|---|---|---|---|---|---|---|
| EVENT | Author (N studies) | Pooled estimate (95% CI) | NNTNNH | Absolute Difference (%/patient year) | Person years exposure for one less or one extra event | Events averted or events incurred for 10,000 persons followed up for 10 years |
| All-cause mortality | Raju [37] (9) | RR 0.94 (0.88–1.00) | 314** | 2,752* | 36* | |
| 2,172** | 46** | |||||
| All-cause mortality | Berger [19] (9) | RR 0.94 (0.89–1.00) | 318** | 2,996* | 33* | |
| 2,198** | 46 ** | |||||
| All-cause mortality | Rothwell [28] ^ (8) | OR 0.92 (0.85–1.00) | 85* | |||
| 75** | ||||||
| All-cause mortality | Rothwell [28] ^^ (3) | HR 0.96 (0.90–1.02) | ||||
| Cancer mortality ~ 7 year follow up | Seshasai [38] (8) | OR 0.93 (0.84–1.03) | 677** | 5,974* | 17* | |
| 4,779** | 21** | |||||
| Cancer mortality | Rothwell [28] ^ (8) | OR 0.79 (0.68–0.92) | 85* | |||
| 54** | ||||||
| Cancer mortality | Rothwell [28] ^^ (3) | HR 0.80 (0.72–0.88) | ||||
| Cancer mortality | Rothwell [20] ^ (51) | OR 0.84 (0.75–0.94) | 319** | 25* (36 assumes mean follow up 7 years) | ||
| 31** (44 assumes mean follow up 7 years) | ||||||
| Colo-rectal cancer death ~ 20 year follow up | Rothwell [13] (4) | OR 0.66 (0.51–0.85) | 0.034*** | 34*36 | ||
| 0.036 | ||||||
| MI / stroke / CV death | ATT [41] IPD (6) | RaR 0.88 (0.82–0.94) | -0.06 | 1,667 | 60 | |
| MI / stroke / CV death | Berger [19] (9) | RR 0.90 (0.85–0.96) | 171** | 1,676* | 60* | |
| 1,184** | 84** | |||||
| Total CHD | Seshasai [38] (9) | OR 0.86 | 226** | 2,146* | 47* | |
| (0.74–1.01) | 1,564** | 64** | ||||
| Total CHD | Bartolucci [18] (9) | OR 0.85 (0.69–1.06) | NC | NC | NC | |
| Non-trivial bleed | Seshasai [38] (9) | OR 1.31 (1.14–1.50) | 146** | 562 | 178* | |
| 1010** | 99** | |||||
| Major bleed | Berger [19] (9) | RR 1.62 | 293** | 2,082 | 48* | |
| (1.31–2.00) | 2,208 | 49** | ||||
| Major bleed | Raju [37] (7) | RR 1.66 | 312** | 2078* | 48* | |
| (1.41–1.95) | 2186** | 46** | ||||
| Major bleed | ATT [41] IPD (6) | RaR 1.54 (1.30–1.82) | 0.030 | 3333 | 30 | |
| GI bleed | Raju [37] (8) | RR 1.37 (1.15–1.62) | 211* | 853** | 117** | |
| 1476* | 68* | |||||
| Haemorrhagic stroke | Raju [37] (8) | RR 1.36 (1.01–1.82) | 534* | 10,516* | 10* | |
| 4,080** | 25** | |||||
| Haemorrhagic stroke | Berger [19] (8) | RR 1.35 (1.01–1.82) | 1421* | 11,165** | 9** | |
| 10,798* | 9* | |||||
| Haemorrhagic stroke | ATT [41] IPD (6) | RaR 1.32 (1.00–1.74) | 0.01# | 10# | ||
| 0.00818## | 8## |
CHD = coronary heart disease; MI = myocardial infarction; GI = gastrointestinal; RaR = rate ratio; RR = risk ratio; OR = odds ratio; HR = hazard ratio; NC = not calculated because individual patient and event numbers not reported.
* aggregate method; ** alternative method; *** aggregate data from Figure 1 of Rothwell 2010 [13] (119 colorectal deaths / 8282 aspirin users and 121colorectal deaths / 5751 aspirin “non-users”, over 20 years of follow up (including approximately 5 years of scheduled aspirin use); # based on rounded data; ## based on unrounded aggregate data; ^ assumes mean follow up of 10 years; ^^ follow up 20 years; Cancer mortality refers to death from any cancer.